Infectious diseases contribute to more than 25% of human morbidity. The arsenal of antimicrobial agents is rapidly being depleted as existing pathogens continue to develop resistance against most of the frontline drugs. According to O’Neill commission, Antimicrobial resistance (AMR) is predicted to incur a huge dent to world economy and cost 10 million lives by 2050. Biofilms and intracellular forms of pathogens have no dedicated treatment and are recalcitrant to antibiotics. To counter these problems, Altibiotics has two lead anti-infective solutions: a new class of drugs and an improved formulation of drugs. Specifically, the new class of drugs are small molecules that kill multi-drug resistant bacteria and fungi by targeting the membrane and the new formulation is that of a Amphotericin B that renders it water soluble, more active and less toxic. These two inventions are expected to improve life expectancy in millions of patients globally who suffer from infections caused by bacteria, fungi and/or parasites.
|Goal/ Vision:||The final goal is to provide at least two clinically approved drug formulations towards infectious diseases. The specific diseases we are trying to address are diabetic foot ulcers, cryptococcosis and leishmaniasis.|
|Institute:||Max Planck Institute of Colloids and Interfaces (currently working at Institute for
Molecular Infection Biology, Wuerzburg)